ANZUP Cancer Trials Group
The Australian genitourinary trials group behind TheraP and proPSMA, the trials that put PSMA imaging and lutetium-PSMA therapy on the map.
Overview
Formed in 2008 to unite Australia and New Zealand's prostate, kidney, bladder, testicular and penile cancer researchers. ANZUP 1603 TheraP was the first randomised trial of lutetium-177 PSMA-617, showing higher PSA response than cabazitaxel and paving the way for VISION and the Pluvicto approval, and proPSMA (ANZUP 1702) showed PSMA PET-CT outperforms conventional imaging for staging high-risk prostate cancer. ENZAMET and ENZARAD tested enzalutamide with docetaxel and with radiotherapy. Trials are run through the NHMRC Clinical Trials Centre at the University of Sydney, and consumer advisory panels are built into every study.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to Australian and New Zealand Urogenital and Prostate Cancer Trials Group, including child institutions. 2 works · 8 citations · 50% open access · 50% clinical trials · 0% reviews.
- Margaret Mary McJannett1 works
- Michelle Frances Morris1 works
- Natasha Anne Roberts1 works
- Michelle Harrison1 works
- Craig R. Underhill1 works
- Ganessan Kichenadasse1 works
- Jeffrey C.H. Goh1 works
- Kathryn Schubach1 works
- Elizabeth Jane Hovey1 works
- Felicia T. Roncolato1 works
| Work | Journal | Year | Citations |
|---|---|---|---|
| Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma. conference abstract · 10.1200/jco.2022.40.16_suppl.4537 | Journal of Clinical Oncology | 2022 | 6 |
| The impact of coronavirus disease 2019 on genitourinary and prostate cancer care and clinical trials: A qualitative exploration of the Australian and New Zealand experience 10.1111/ajco.13847 · open access | Asia-Pacific Journal of Clinical Oncology | 2022 | 2 |
- TheraP (Lu-PSMA vs cabazitaxel)
- proPSMA (PSMA PET staging)
- ENZAMET / ENZARAD
- Bladder and kidney cancer trials
- Consumer involvement
Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.
Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.
Runs the medical oncology side of Peter Mac's theranostics programme, combining lutetium-PSMA with hormonal and immune therapies.
Similar pages
not linked directly; found by shared links- Key paperTheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer
Shares Shahneen Sandhu, Michael Hofman, TheraP (ANZUP 1603), Lutetium-177 vipivotide tetraxetan.
- PersonRodney J. Hicks
Shares proPSMA, Peter MacCallum Cancer Centre, Lutetium-177 vipivotide tetraxetan, Lutetium-177.
- IdeaAdding a checkpoint inhibitor to PSMA radioligand therapy
Shares Shahneen Sandhu, TheraP (ANZUP 1603), Lutetium-177 vipivotide tetraxetan, Lutetium-177.
- Key paperLuPSMA trial: single-arm phase 2 study of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer
Shares Michael Hofman, TheraP (ANZUP 1603), PSMA PET, Lutetium-177.
- PersonRahul Aggarwal
Shares Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Theranostics, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PairingPSMA PET → PSMA radioligand therapy
Shares Theranostics, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).